ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $214,777 | -17.2% | 10,306 | -4.8% | 0.15% | -10.1% |
| Q2 2023 | $259,354 | +25.2% | 10,829 | -1.6% | 0.17% | +23.4% |
| Q1 2023 | $207,170 | +18.2% | 11,008 | 0.0% | 0.14% | +11.4% |
| Q4 2022 | $175,247 | -2.6% | 11,008 | 0.0% | 0.12% | -10.9% |
| Q3 2022 | $180,000 | +16.1% | 11,008 | 0.0% | 0.14% | +21.1% |
| Q2 2022 | $155,000 | -52.7% | 11,008 | -18.6% | 0.11% | -43.8% |
| Q1 2022 | $328,000 | +20.1% | 13,516 | +15.8% | 0.20% | +18.0% |
| Q4 2021 | $273,000 | +34.5% | 11,672 | -4.1% | 0.17% | +22.0% |
| Q3 2021 | $203,000 | -31.2% | 12,172 | 0.0% | 0.14% | -9.6% |
| Q2 2021 | $295,000 | -6.1% | 12,172 | 0.0% | 0.16% | -12.8% |
| Q1 2021 | $314,000 | -51.8% | 12,172 | 0.0% | 0.18% | -57.1% |
| Q4 2020 | $651,000 | -28.1% | 12,172 | -44.5% | 0.42% | -25.4% |
| Q3 2020 | $905,000 | – | 21,921 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |